BioTech Maxion Therapeutics has raised a £58m Series A investment round to develop its technology and address large global markets. The Cambridge-based firm is currently developing antibody-based KnotBody drugs for ion channel and G protein coupled receptor (GPCR) driven diseases. Its lead KnotBody programme, MAX001, is currently in preclinical development to target inflammatory diseases such … Continue reading Cambridge BioTech raises £58m to target global markets